DK1163239T3 - Modified amino acid amides as CGRP antagonists - Google Patents

Modified amino acid amides as CGRP antagonists

Info

Publication number
DK1163239T3
DK1163239T3 DK00922505T DK00922505T DK1163239T3 DK 1163239 T3 DK1163239 T3 DK 1163239T3 DK 00922505 T DK00922505 T DK 00922505T DK 00922505 T DK00922505 T DK 00922505T DK 1163239 T3 DK1163239 T3 DK 1163239T3
Authority
DK
Denmark
Prior art keywords
amino acid
acid amides
modified amino
cgrp antagonists
cgrp
Prior art date
Application number
DK00922505T
Other languages
Danish (da)
Inventor
Wolfgang Eberlein
Klaus Rudolf
Wolfhard Engel
Henri Doods
Gerhard Hallermayer
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1163239T3 publication Critical patent/DK1163239T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK00922505T 1999-03-12 2000-03-08 Modified amino acid amides as CGRP antagonists DK1163239T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19911039A DE19911039A1 (en) 1999-03-12 1999-03-12 Modified amino acid amides, pharmaceutical compositions containing these compounds and process for their preparation
PCT/EP2000/002004 WO2000055154A1 (en) 1999-03-12 2000-03-08 Modified amino-acid amides as cgrp antagonists

Publications (1)

Publication Number Publication Date
DK1163239T3 true DK1163239T3 (en) 2003-09-08

Family

ID=7900727

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00922505T DK1163239T3 (en) 1999-03-12 2000-03-08 Modified amino acid amides as CGRP antagonists

Country Status (13)

Country Link
EP (1) EP1163239B1 (en)
JP (1) JP3719937B2 (en)
AR (1) AR022906A1 (en)
AT (1) ATE241616T1 (en)
AU (1) AU4288000A (en)
CA (1) CA2361939A1 (en)
CO (1) CO5150226A1 (en)
DE (2) DE19911039A1 (en)
DK (1) DK1163239T3 (en)
ES (1) ES2199819T3 (en)
PT (1) PT1163239E (en)
UY (1) UY26057A1 (en)
WO (1) WO2000055154A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
DE19937304C2 (en) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Use of CGRP antagonists to combat menopausal hot flashes
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
EP1456198A1 (en) 2001-12-12 2004-09-15 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
PL374017A1 (en) 2002-06-05 2005-09-19 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
DE10227294A1 (en) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparations for intranasal application of selected amino acid-derived CGRP antagonists and processes for their preparation
RS52750B (en) 2002-08-12 2013-08-30 Birkir Sveinsson Use of cgrp antagonist compounds for treatment of psoriasis
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (en) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
EP1689493A4 (en) 2003-12-05 2008-04-23 Bristol Myers Squibb Co Calcitonin gene related peptide receptor antagonists
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
DE102004006893A1 (en) * 2004-02-12 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of 1 [N 2 - [3,5-dibromo-N - [[4- (3,4-dihydro-2 (1H) -oxoquinazolin-3-yl) -1-piperidinyl] carbonyl] -D-tyrosyl ] -L-lysyl] -4- (4-pyridinyl) -piperazine
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
JP2007533685A (en) * 2004-04-20 2007-11-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of a CGRP antagonist in combination with a serotonin reuptake inhibitor to treat migraine
EP1619187A1 (en) * 2004-07-23 2006-01-25 Boehringer Ingelheim Pharma GmbH & Co. KG Process for the preparation of 3-(4-piperidinyl)- 2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-on
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US7473778B2 (en) 2005-12-24 2009-01-06 Boehringer Ingelheim International Gmbh 3-(4-piperidinyl)-2,3,4,5-tetrahydro-1,3-benzodiazepin-2(1H)-one
WO2009050234A1 (en) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh Cgrp antagonists
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
US11433119B2 (en) 2016-11-18 2022-09-06 Nepsone Ehf Methods of treating inflammatory skin disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004037B1 (en) * 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Modified aminoacids, pharmaceuticals on their base
US6552043B1 (en) * 1998-09-30 2003-04-22 Merck Sharpe & Dohme Ltd. Benzimidazolinyl piperidines as CGRP ligands

Also Published As

Publication number Publication date
CO5150226A1 (en) 2002-04-29
JP3719937B2 (en) 2005-11-24
AU4288000A (en) 2000-10-04
DE19911039A1 (en) 2000-09-14
AR022906A1 (en) 2002-09-04
CA2361939A1 (en) 2000-09-21
ATE241616T1 (en) 2003-06-15
ES2199819T3 (en) 2004-03-01
EP1163239A1 (en) 2001-12-19
JP2002539208A (en) 2002-11-19
UY26057A1 (en) 2000-10-31
PT1163239E (en) 2003-10-31
EP1163239B1 (en) 2003-05-28
DE50002364D1 (en) 2003-07-03
WO2000055154A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
DK1163239T3 (en) Modified amino acid amides as CGRP antagonists
NO20026252D0 (en) AZA Bridge - Bicyclic amino acid derivatives as alpha 4 integrin antagonists
NO20021450D0 (en) Cyclic amine compounds as CCR5 antagonists
NO20021780D0 (en) Bicyclic amino acids as pharmaceutical agents
NO20040028L (en) Substituted aniline piperidines as MCH-selective antagonists
DK1218359T3 (en) Piperazine compounds as tachykinin antagonists
ATE374191T1 (en) UREA DERIVATIVES AS INTEGRIN ALPHA 4 ANTAGONISTS
NO20015366D0 (en) Piperazine derivatives useful as CCR5 antagonists
NO20020307L (en) N- (indolecarbonyl) -piperazine
NO20014483D0 (en) Amine derivatives as protease inhibitors
DK1218383T3 (en) Biocyclic imidazo-5-yl amino derivatives
EE200000428A (en) VLA-4 antagonists
DK1216250T3 (en) Thienoisoxazolyl and thienylpyrazolyl-phenoxy-substituted propyl derivatives as D4 antagonists
ATE392418T1 (en) SUBSTITUTED FLUORALKOXYPHENYLSULFONYL UREAS
DE60222693D1 (en) NK1 ANTAGONISTS
DE60207399D1 (en) ALKOXYCARBONYLAMINOBENOIC ACID OR ALKOXYCARBONYLAMINOTETROZOLYLPHENYL DERIVATIVES AS IP ANTAGONISTS
NO20015237D0 (en) Integrin antagonists
ATE297919T1 (en) SUBSTITUTED THIENYL(AMINO)SULFONYL UREAS
DE50003014D1 (en) N-SUBSTITUTED PERHYDRODIAZINE
ID26508A (en) SUBSTITUTED OXIMS AS NEUROKININ ANTAGONISTS
DE60134427D1 (en) EXCITATIVE AMINO ACID RECEPTOR ANTAGONISTS
NO20021249L (en) Tienoisoxazolphenoxy substituted ethyl and propyl derivatives useful as D4 antagonists
FI20000395A (en) N- (amidinobenzoyl or amidinopyridylcarbonyl) -alpha-amino acid derivatives
DK1226110T3 (en) Bicyclic amino acids as pharmaceuticals
ITRM990062U1 (en) PROJECT X